EnteroMedics Director Sells $1,391,463 in Stock (ETRM)
EnteroMedics (NASDAQ:ETRM) Director Luke Evnin unloaded 556,585 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $2.50, for a total transaction of $1,391,462.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
EnteroMedics (NASDAQ:ETRM) traded up 3.17% during mid-day trading on Thursday, hitting $2.60. The stock had a trading volume of 799,571 shares. EnteroMedics has a 52 week low of $0.81 and a 52 week high of $3.23. The stock has a 50-day moving average of $1.8 and a 200-day moving average of $1.35. The company’s market cap is $157.8 million.
EnteroMedics (NASDAQ:ETRM) last released its earnings data on Thursday, October 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). On average, analysts predict that EnteroMedics will post $-0.47 earnings per share for the current fiscal year.
A number of research firms have recently commented on ETRM. Analysts at Craig Hallum raised their price target on shares of EnteroMedics to $6.00 in a research note to investors on Monday. Separately, analysts at Roth Capital raised their price target on shares of EnteroMedics from $2.00 to $3.00 in a research note to investors on Wednesday, December 4th. Finally, analysts at Northland Securities raised their price target on shares of EnteroMedics from $3.00 to $7.00 in a research note to investors on Tuesday, December 3rd. They now have an “average” rating on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $4.83.
EnteroMedics Inc (NASDAQ:ETRM) is a development- stage medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.